Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) EBITDA (2023 - 2025)

Incannex Healthcare's EBITDA history spans 3 years, with the latest figure at -$6.8 million for Q4 2025.

  • For Q4 2025, EBITDA fell 7.67% year-over-year to -$6.8 million; the TTM value through Dec 2025 reached -$48.3 million, down 98.46%, while the annual FY2025 figure was -$46.7 million, 152.43% down from the prior year.
  • EBITDA for Q4 2025 was -$6.8 million at Incannex Healthcare, down from -$6.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$1.2 million in Q3 2023 and bottomed at -$31.3 million in Q2 2025.
  • The 3-year median for EBITDA is -$6.1 million (2024), against an average of -$7.8 million.
  • The largest YoY upside for EBITDA was 40.8% in 2025 against a maximum downside of 412.46% in 2025.
  • A 3-year view of EBITDA shows it stood at -$4.3 million in 2023, then plummeted by 46.22% to -$6.3 million in 2024, then decreased by 7.67% to -$6.8 million in 2025.
  • Per Business Quant, the three most recent readings for IXHL's EBITDA are -$6.8 million (Q4 2025), -$6.2 million (Q3 2025), and -$31.3 million (Q2 2025).